---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

#### Serious hypersensitivity reactions: program-level incidence

> “Hypersensitivity reactions led to early discontinuation of study drug in 3 participants”
> “Two participants with serious allergic reactions (including anaphylaxis)”
> “Resolved quickly upon discontinuation of study drug”
> “Overall program incidence of ~2%”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

> “Two of the study participants experienced serious hypersensitivity reactions which led to early discontinuation of study drug.”
> “The incidence of serious allergic reactions across the program is relatively low compared to biologic or monoclonal antibody treatments.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.7.1-3"></a>

#### Known allergy to ersodetug: exclusion criterion in the tumor hyperinsulinism trial

> “Known allergy or sensitivity to ersodetug or any component of the drug.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.1.2.7.1-4"></a>

#### Hypertrichosis

> “Excess hair growth (hypertrichosis) was commonly reported in ersodetug treated patients (~35%)”
> “Mild and not dose-dependent”
> “Led to discontinuation of study drug in 1 participant”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

> “The most commonly reported study adverse event in ersodetug treated participants compared to placebo was hypertrichosis, which was generally mild and self-limiting.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.7.1-5"></a>

#### Hyperglycemia and hepatic safety monitoring: congenital hyperinsulinism program

> “No clinically-relevant hyperglycemia”
> “Low rates of transient mild to moderate hyperglycemia without associated sequalae”
> “No hyperglycemia AEs”
> “Hepatic safety: No signal by liver enzymes or ultrasound monitoring”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-2.1.2.7.1-6"></a>

#### Safety in tumor hyperinsulinism under expanded access

> “Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.”
> “There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.”
> “No hyperglycemia-related adverse events or need for insulin were reported.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “No participants have discontinued the therapy due to lack of response or safety, and the duration of treatment has ranged from several months to more than 2 years in some instances, in this subset of tumor HI patients with significantly advanced and metastatic tumor burden.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.7.1-7"></a>

#### Nonclinical liver findings in Sprague Dawley rats

> “As part of the effort to resolve the partial clinical holds in the U.S., the Company conducted and recently completed an in-vivo toxicology study in brown Norway rats using Sprague Dawley (SD) rats as a positive control.”
> “Early results show that at the highest tested dose of 40 mg/kg, there were no observed liver abnormalities in the brown Norway rat, which is approximately four times higher than the dose that results in microvascular liver abnormalities in SD rats.”
> “Additionally, at the 40 mg/kg dose in this study, SD rats had liver abnormalities consistent with previous in-vivo studies.”
> “The Company believes that the Norway rat study adds to the body of evidence that the rat findings are specific to the SD rat and are not otherwise relevant, based on the absence of findings in other rat strains, other rodent species (CD-1 mice), primates, and humans in studies to date.”

Source: [Rezolute third quarter fiscal 2024 results release (2024)](https://ir.rezolutebio.com/news/detail/329/rezolute-reports-third-quarter-fiscal-2024-financial-results-and-provides-business-update)

<a id="topic-2.1.2.7.1-8"></a>

#### Partial clinical holds on congenital hyperinsulinism studies and their scope

> “In the January Meeting, FDA indicated that current dose caps on cHI studies would not be applicable to taHI studies.”
> “Therefore, considering the indication is primarily adult, current partial clinical holds pertaining to cHI studies would be largely irrelevant in taHI.”
> “The Company remains engaged with FDA in the attempt to resolve ongoing partial clinical holds on clinical studies in the cHI indication.”

Source: [Rezolute second quarter fiscal 2024 results release (2024)](https://ir.rezolutebio.com/news/detail/326/rezolute-reports-second-quarter-fiscal-2024-results-and-provides-business-update)

<a id="topic-2.1.2.7.1-9"></a>

#### Removal of the partial clinical holds in September 2024

> “today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical holds on RZ358 (ersodetug), a potential treatment for hypoglycemia caused by congenital HI.”
> “are allowing us to proceed in the U.S. at all doses and in participants as young as three months of age as part of our ongoing global study”
> “FDA specifically concluded that the liver toxicity observed in Sprague Dawley rats is likely strain-specific and not otherwise relevant to humans”

Source: [Rezolute partial clinical hold release (2024)](https://ir.rezolutebio.com/news/detail/339/fda-lifts-partial-clinical-holds-on-rz358-for-the-treatment-of-congenital-hyperinsulinism-and-authorizes-u-s-inclusion-in-ongoing-phase-3-study)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
